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ARTICLE
Germline AGO2 mutations impair RNA interference
and human neurological development
Davor Lessel et al.#
ARGONAUTE-2 and associated miRNAs form the RNA-induced silencing complex (RISC),
which targets mRNAs for translational silencing and degradation as part of the RNA inter-
ference pathway. Despite the essential nature of this process for cellular function, there is
little information on the role of RISC components in human development and organ function.
We identify 13 heterozygous mutations in AGO2 in 21 patients affected by disturbances in
neurological development. Each of the identified single amino acid mutations result in
impaired shRNA-mediated silencing. We observe either impaired RISC formation or
increased binding of AGO2 to mRNA targets as mutation specific functional consequences.
The latter is supported by decreased phosphorylation of a C-terminal serine cluster involved
in mRNA target release, increased formation of dendritic P-bodies in neurons and global
transcriptome alterations in patient-derived primary fibroblasts. Our data emphasize the
importance of gene expression regulation through the dynamic AGO2-RNA association for
human neuronal development.
https://doi.org/10.1038/s41467-020-19572-5 OPEN
#A list of authors and their affiliations appears at the end of the paper.









RNA interference is a major mechanism for post-transcriptional regulation of gene expression. Precursorsof microRNAs (miRNAs) are transcribed, processed into
mature miRNAs and loaded onto Argonaute (AGO1-4) proteins
to form the RNA-induced silencing complex (RISC)1. Each
miRNA may recognize a set of target mRNAs by base pairing2,
which leads to translational silencing and mRNA degradation in
cytoplasmic structures referred to as processing (P-) bodies3–5.
Biallelic loss of Ago2 leads to early embryonic lethality in mice
exhibiting various development defects including anomalies
of the central nervous system6. Therefore, accurate regulation of
gene expression by the RNA interference pathway seems to be
of utmost importance for proper development and maintenance
of complex neural circuits7,8. However, so far no genetic altera-
tions in the gene encoding for AGO2 have been described which
are associated with any human pathology. Thus, it still remains
largely elusive how RNA interference, and especially domains of
AGO2 or local sequences down to single amino acid residues,
regulate human organismal development and function.
Here, we demonstrate that germline AGO2 mutations affect
human neurological development and provide molecular insight
into how AGO2 dysfunction causes a human Mendelian disorder.
Results
Identification of patients bearing germline AGO2 mutations.
During trio whole-exome sequencing of a cohort of 50 children
affected by developmental disturbances and neurological mani-
festations of unknown etiology9, we identified a patient bearing a
de novo missense mutation p.L192P in AGO2 (NM_012154.5).
Based on the ExAC and gnomAD sequencing data, AGO2
is one of the most missense-intolerant genes in the human gen-
ome, ranked 15 and 30 respectively. Its Z scores of 7.696
(ExAC dataset) and 6.058 (gnomAD dataset) are far higher than
the average Z score for genes involved in developmental
disorders10–12. Only two AGO2 non-synonymous alterations (p.
G88V and p.E186K) with an allele frequency of more than 0.0001
are deposited in ExAC and gnomAD datasets. Moreover, the p.
L192P variant was not present in publicly available datasets
(dbSNP, ExAC and gnomAD), had a high in silico pathogenic
prediction score (CADD_Phred of 27.1) and changed a highly
conserved residue (Supplementary Fig. 1). Furthermore, a pre-
vious study aiming to identify de novo variants in 20 individuals
with sporadic non-syndromic intellectual disability identified a de
novo p.L190P in AGO113. The leucine at position 192 in AGO2
corresponds to the leucine at position 190 in AGO1 (Supple-
mentary Fig. 1). In addition, five individuals affected by neuro-
developmental disturbances bearing a deletion that encompasses
both AGO1 and AGO3 have been documented previously14.
These findings motivated us to search for further cases carrying
heterozygous AGO2 variants utilizing both the internet-based
GeneMatcher tool15, and direct contact to our network of
collaborators.
This approach led to identification of altogether 21 patients,
including our index patient, affected by mild to severe global
neurodevelopmental delay, who were discovered either by whole-
exome sequencing or microarray-based comparative genomic
hybridization. Eleven missense mutations, one in-frame deletion
(Fig. 1a) and a 235.3-kb deletion involving the first three exons
occurred de novo (Fig. 1b). In addition, one of the missense
mutations (p.T357M) was transmitted from a similarly affected
mother. Five mutations (p.L192P, p.G201V, p.T357M, p.M364T,
p.C751Y) were recurrent. None of the mutations were present in
publicly available datasets, and similarly to p.L192P, all missense
mutations display high in silico pathogenic prediction scores
(mean CADD_Phred of 29.1) and change highly conserved
residues (Supplementary Data 1; Supplementary Fig. 1). Thus, the
genetic data, especially the recurrence of mutations, already
provide strong evidence for their pathogenicity.
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Fig. 1 Location of identified AGO2 germline mutations. a Domain structure of AGO2 and position of the single amino acid mutations using the structure of
human AGO2 in complex with a miRNA and a target RNA22. Guide and target RNA are depicted in orange and red, respectively. The recurring mutations
are designated in brackets. b Genomic region, chr8.hg19:g.(141,582,269-141,817,600)del, of the 235.3-kb deletion identified in case 21, involving the first
three AGO2 exons and the last 23 PTK2 exons.
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The 21 individuals show overlapping phenotypes, summarized
in Table 1, and in more detail in Supplementary Note 1 and
Supplementary Fig. 2. All individuals displayed intellectual
disability, albeit of variable degree, as well as delayed motor
development, impaired speech and receptive language develop-
ment (13/13). Twelve patients had hypotonia (57%) and ten had
gait abnormalities (10/18, 55%). Nine patients (9/16, 56%)
showed features of autism spectrum disorder, including stereo-
typic and hand-flapping behavior, eight patients (8/15, 53%)
showed features consistent with attention deficit hyperactivity
disorder, and four (4/17, 24%) developed aggressive behavior,
predominantly upon entering puberty. Eight patients developed
seizures (8/18, 44%). Brain anomalies on MRI, mainly affecting
the corpus callosum, were observed in nine patients (9/16, 56%).
Vision problems included visual impairment in six (29%),
strabismus in seven (33%) and myopia or hyperopia in four
(19%) patients. Various breathing abnormalities were observed in
five (5/19, 26%) and included central apnea in the postnatal
period (observed in both cases carrying the p.L192P mutation),
sleep apnea and hypopnea. Craniofacial abnormalities included
epicanthic folds (57%), thin upper lip (52%), frontal bossing
(43%), open mouth appearance (43%), deep-set eyes (43%),
upslanting palpebral fissures (29%), congenital anomalies of the
skull (29%) including plagiocephaly (5/21) and scaphocephaly (1/
21), various ear helix anomalies (24%) and broad nasal bridge
(14%). Dental anomalies were observed in nine (9/19, 47%).
Twelve had neonatal feeding difficulties (12/19, 63%). Skeletal
anomalies, not including congenital anomalies of the skull, were
observed in nine patients (9/19, 47%). Notably, all three
individuals carrying the p.C751Y mutation had bilateral clin-
odactyly of the 5th finger. Seven individuals experienced
gastroesophageal reflux (7/19, 37%). Heart anomalies were
observed in six patients (6/18, 33%), whereas three of them had
patent foramen ovale.
Spatial clustering of residues affected by germline AGO2
mutations. AGO2 consists of N-terminal (N), Piwi/Argonaute/
Zwille (PAZ), middle (MID) and PIWI (P-element induced
wimpy testis) domains which are connected by linker regions L1
and L2 (Fig. 1a). The N domain is indispensable for RNA
unwinding during RISC formation16. The PAZ domain binds to
the 3′ end of the guide RNA and is involved in RISC
activation17,18. The MID domain provides a binding pocket for
the 5′ end of the guide RNAs19. The PIWI domain harbors a
conserved catalytic core that cleaves the passenger strand, med-
iates protein-protein interactions needed for the enrollment of
GW182, and regulates the interaction between RNA and the MID
domain20,21. Binding determinants for miRNA (in the AGO2/
miRNA RISC) and the structural changes occurring upon
engagement of mRNA targets have been identified through
structural analyses22,23. An α-helical segment in the L2 linker
(helix-7, residues 359-369) is responsible for the proper posi-
tioning of the guide RNA during scanning of target mRNAs; here,
residue I365 intercalates between guide RNA bases and induces a
conformational change which is required for rapid target recog-
nition24. We identified three mutations in helix-7: p.T357M (four
patients), p.M364T (two patients) and p.A367P. All three residues
face towards the L1 linker and are in close spatial proximity to
L192 in L1, mutated in two patients (p.L192P). Upon target
mRNA recognition, helix-7 and the PAZ domain move relative to
the rest of the protein by 4 Å, to accommodate the target mRNA
strand22. The hinge for this movement is partially localized at the
base of L1, where we identified p.F182del, p.G201C, p.G201V
(two patients) and p.H203Q; this is a region of the protein which
has previously been implicated in the unwinding of RNA
duplexes16. Finally, mutations p.G733R, p.C751Y (three patients,
including monozygotic twins) and p.S760R affect residues which
are in direct contact to each other, and located at the base of a
loop in the PIWI domain which binds to the minor groove in the
guide/target duplex22. Thus, we identify three spatial clusters of
mutations: at the helix-7/L1 interface, at the hinge region of L1,
and in a loop in PIWI which recognizes the guide-target duplex
(Supplementary Fig. 3). Only p.G573S affects a residue outside of
these clusters at the C-terminal end of the MID domain (Fig. 1a).
In addition, the de novo (as determined by qPCR analysis) long-
range deletion affecting the first three AGO2 exons (Fig. 1b) is
likely to result in haploinsufficiency (Supplementary Fig. 4),
similar to deletions affecting both AGO1 and AGO314.
AGO2 germline mutations impair shRNA-mediated silencing.
To analyze how single amino acid mutations affect AGO2 func-
tion, we deleted AGO2 in human HEK293T cells using CRISPR/
Cas9-technology. Complete loss of AGO2 was confirmed by
Western blotting (Supplementary Fig. 5). We used three shRNAs
which had been established before in the lab and shown to be
effective in reducing expression of Shank3, δ-catenin and DDX1,
respectively. In line with the previously established essential role
of AGO2 in shRNA-mediated gene silencing25, strongly reduced
silencing activity was observed for these shRNAs in AGO2 defi-
cient cells, as they did not silence coexpressed Shank3 (Fig. 2a),
DDX1 (Fig. 2b) and δ-catenin (Fig. 2c and Supplementary Fig. 6)
mRNAs. Re-expression of WT-AGO2 efficiently rescued this
phenotype, with residual expression of target proteins Shank3
of about 20%, and DDX1 and δ-catenin of <2% compared to




Intellectual disability 21/21 100 %
Motor developmental delay 21/21 100%
Impaired speech development 21/21 100%
Impaired receptive language 13/13 100%
Muscular hypotonia 12/21 57%
Autistic features 9/16 56%
Cerebral MRI abnormalities 9/16 56%
Gait abnormalities 10/18 55%
Attention deficit hyperactivity disorder 8/15 53%
Seizures 8/18 44%
Strabism 7/21 33%
Visual impairment 6/21 29%
Abnormal respiration 5/19 26%
Agressive behavior 4/17 24%
Myopia/Hyperopia 4/21 19%
Craniofacial abnormalities
Epicanthic folds 11/21 52%
Thin upper lip 11/21 52%
Dental anomalies 9/19 47%
Frontal bossing 9/21 43%
Open mouth appearance 9/21 43%
Deep set eyes 9/21 43%
Upslanting palpebral fissures 6/21 29%
Congenital anomalies of the skull 6/21 29%
Helix anomalies 5/21 24%
Broad nasal bridge 3/21 14%
Other findings
Neonatal feeding difficulties 12/19 63%
Skeletal anomalies 9/19 47%
Gastroesophageal reflux 7/19 37%
Heart anomalies 6/18 33%
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19572-5 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:5797 | https://doi.org/10.1038/s41467-020-19572-5 |www.nature.com/naturecommunications 3
AGO2-deficient cells. All mutants were significantly less efficient
than WT AGO2 in Shank3 silencing, whereas only some of the
mutations showed significant effects for DDX1 and δ-catenin
(Fig. 2a–e), suggesting target mRNA specific effects of some
mutations. We further used this experimental system to investi-
gate whether AGO2 variants may exert a dominant-negative effect
on the function of the WT AGO2 protein. Notably, we observed
that knockdown of DDX1 expression by the DDX1 shRNA in the
presence of F/H-tagged WT AGO2 was not affected by coex-
pression of selected mutant GFP-tagged AGO2 (p.L192P; p.
M364T or p.G733R; see Fig. 2f). Thus, these data suggest that, at
least the analyzed mutants, result in a loss-of-function.
a
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As the abovementioned experiments were performed by
overexpression of AGO2 variants, we next carefully calibrated
our experimental system over a wide range of WT AGO2
concentrations. In brief, we transfected different amounts of
AGO2 expression vectors into the AGO2 deficient cells, while
keeping amounts of cotransfected shRNA (for δ-catenin) and
target vector (GFP-δ-catenin) constant. AGO2 expression relative
to native HEK293T cells ranged from 54 % for WT AGO2, when
the lowest concentrations of DNA was used (0.1 µg), to an about
20-fold overexpression when 1 µg was transfected into each well
of a 12 well plate (Supplementary Fig. 6). Interestingly, the
silencing efficiency of WT AGO2 was maintained almost
unaltered over this wide range of concentrations. Even at
expression levels which are lower than those in unmodified
HEK293T cells, efficient downregulation of δ-catenin was
observed. Importantly, both at low and at high concentrations
of AGO2, differences between WT and mutant forms of AGO2
were maintained, such that even at more than 10-fold over-
expression, the p.F182del, p.L192P, and p.G733R variants did not
silence as efficiently as AGO2 WT at its lowest concentration
(Supplementary Fig. 6).
We conclude from these titration experiments that strong
differences between WT and mutant forms of AGO2 are observed
at physiological levels of the protein (i.e., at levels found in the
non-modified HEK293T cell line).
RISC formation is differentially affected by germline AGO2
mutations. Having established a functional deficit for all single
amino acid mutations, we used a spectrum of assays to determine
which step of the miRNA pathway might be affected. We tested
the ability of AGO2 variants to interact with DICER, the protein
responsible for pre-miRNA processing and loading of the mature
miRNA onto AGO2 (Supplementary Fig. 7), and with the pro-
teins of the TNRC6 family that associate with AGO proteins
during miRNA-guided gene silencing (Supplementary Fig. 8). We
further assessed the capacity to bind to an endogenous miRNA
(miR19-b) in HEK293T cells (Supplementary Fig. 8), the nuclease
or slicing function of the AGO2 variants in in vitro cleavage
assays using a radiolabeled substrate26 (Supplementary Fig. 9),
and the ability to silence a luciferase-based reporter mRNA in
Hela cells (Supplementary Fig. 10). Finally, correct targeting of
AGO2 to P-bodies3,27 was investigated in U2OS cells (Supple-
mentary Fig. 11). In these assays, most mutants performed similar
to WT-AGO2, with the exception of p.G733R, which appeared to
be non-functional in almost every aspect tested. Thus, mutations
in AGO2 have two functional consequences: first, in the majority
of the mutants, basic aspects of RISC formation and AGO2
function are not affected, and second the p.G733R mutant
exhibits a loss-of-function in almost every assay, likely similar to
the anticipated effect of the here identified 235.3-kb deletion.
Reduced phosphorylation and altered mRNA target release of
germline AGO2 mutations. AGO2 function is regulated by
protein kinases whereby phosphorylation at Ser387 by AKT3
favors translational repression of targets over degradation28.
Importantly, phosphorylation of a C-terminal cluster (S824–S834)
by casein kinase α1 (CSNK1A1) is associated with the final step of
AGO2-mediated mRNA repression, which enhances the release of
the target mRNA from the RISC complex29,30. We measured
phosphorylation of Ser387 and the C-terminal cluster upon
immunoprecipitation of AGO2 from HEK293T cells, followed by
quantitative mass spectrometry. Phosphorylation of S387 was not
altered, whereas phosphorylation of the C-terminal cluster was
strongly reduced in all mutants tested, except for p.H203Q
(Fig. 3a). By performing qRT-PCR on RNA samples isolated from
AGO2 immunoprecipitates, we further observed that all mutants
exhibiting reduced phosphorylation of this cluster also showed an
increased association with a set of known target mRNAs, with the
exception of p.G733R, which did not bind any mRNAs further
supporting a complete loss of function of this mutant (Fig. 3b).
These data further corroborate the link between phosphorylation
of the S824-S834 cluster and the mRNA release from AGO229,30,
and indicate a slower release of the majority of the identified
AGO2 mutants from target mRNAs. Thus, we suggest a model in
which a reduced phosphorylation of the C-terminal serine cluster
of most of the disease-causing mutants coincides with reduced
target release and thus an extended dwelling time of the AGO2
mutants on their targets.
Molecular dynamics simulations suggest an effect of germline
AGO2 mutations on AGO2 unwinding function. To further
clarify the effect of AGO2 mutations, apart from the clear loss-of-
function mutation p.G733R, we performed non-biased molecular
dynamics (MD) simulations. Our goal was to gain further insight
into the effect of the above-mentioned mutations in apo-AGO2
and AGO2-RNA complexes. As a positive control, we included p.
F181A which was shown before in an alanine scanning muta-
genesis to reduce the unwinding of both siRNA and miRNA
duplexes16. As a negative control, we included p.E186K, one of
the two common non-synonymous AGO2 variants found in
public repositories. AGO2 mutations were simulated in five states
corresponding to different complexes along RISC formation: (i)
apo-AGO2; two AGO2 complexes with guide RNA (core-RISC),
namely intercalating (ii; int core-RISC) and non-intercalating (iii;
non- int core-RISC); and two AGO2 complexes with guide-target
duplexes (holo-RISC) with fully matched seed region (iv; g2-7
Fig. 2 Germline AGO2 mutations impair shRNA-mediated silencing. a–c AGO2-deficient HEK293T cells were transfected with mRFP-Shank3 (a), mRFP-
DDX1 (b), or GFP-tagged δ-catenin (c) along with shRNA constructs targeting Shank3 (a; in pLVTHM vector coexpressing GFP), DDX1 (b; in pSuper) or δ-
catenin (c; also in pSuper), and Flag/HA-tagged (Shank3, δ-catenin) or GFP-tagged (for DDX1) AGO2 variants as indicated. Efficient transfection (>70 %
of cells) was verified by fluorescence microscopy using appropriate fluorophores (GFP in (a) and (b); RFP in (c). Cells were lysed and lysates were analysed
by Western Blotting using the antibodies indicated. In each case, each experiment was repeated eight times with similar results. d Quantification of the
representative immunoblots shown in (a–c). The expression levels are relative to those in control cells without an AGO2 construct (first lane in each
immunoblot). e Quantification of a second set of AGO2 mutants. For (d, e), data are means+ SEM. Data for mutant and control conditions were compared
to wt. *, **, ***p < 0.05, 0.01, 0.001, respectively; n= 8 biologically independent experiments in (d); one-way-ANOVA, followed by Holm-Sidak’s multiple
comparisons test; n= 6–14 biologically independent experiments in e for Shank3; mixed-effects analysis, followed by Holm-Sidak’ multiple comparisons
test; n= 6 biologically independent experiments in (e) for δ-catenin; one-way ANOVA, followed by Dunnett’s multiple comparisons test. f Knockdown of
DDX1 with DDX1 shRNA was performed as in (b), but using F/H-tagged AGO2 in combination with GFP, or in combination with GFP-tagged AGO2
variants. Note that the GFP-tagged AGO2 mutants do not interfere with the knockdown capacity of F/H-AGO2 WT. n= 8 biologically independent
experiments; data are means+/− SD; ****p < 0.0001; one-way ANOVA, followed by Dunnett’s multiple comparisons test. Source data are provided as a
Source Data file.
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Fig. 3 Reduced target dissociation of AGO2 germline mutants. a 293 cells were transfected with F/H-tagged AGO2. After immunoprecipitation,
phosphorylation of S824 alone, of the S824–S834 cluster and of S387 was measured by a targeted quantitative mass spectrometry approach (Selected
reaction monitoring with isotopically labeled spike-in peptides). The y-axis represents the percentage of individual phosphorylated peptide species
assuming the sum of singly, multiply and non-phosphorylated peptides to be 100%. Significance was assessed by two-sided Student’s t test in relation to
WT. n= 3 biologically independent experiments. Data are presented as mean+ SD. *, **, ***p < 0.05, 0.01, 0.001, respectively. b RNA was isolated from
F/H–AGO2 immunoprecipitates and analyzed by qRT-PCR using primers for the genes indicated. The significance was assessed by two-sided Student’s t
test in relation to WT. n= 3 biologically independent experiments. Data are presented as mean+ SD. *, **, ***p < 0.05, 0.01, 0.001, respectively. Source
data are provided as a Source Data file.
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holo RISC) or with a mismatch at position 8 of the guide (v; g2-8,
holo RISC). The underlying structures and pdb codes are listed in
Supplementary Fig. 12. This large number of simulations (12
AGO2 variants in five different states) was chosen as an initial
screening approach to identify possible alterations in mutant forms
of AGO2; however, this large number also precluded detailed
quantitative measurements. Among the simulated complexes, the
mutations appeared not to uniformly affect the population dis-
tributions on this conformational mode. Principal component
analysis of apo-AGO2 trajectories suggested that only two muta-
tions, p.L192P and p.F182del, affected global protein dynamics. The
predominant conformational mode of these two variants deviated
from the open-closed mode, previously described as the most
pronounced conformational mode of AGO proteins31 (Supple-
mentary Fig. 13). Further, analyses of the non-biased MD trajec-
tories of RNA-bound complexes suggested two effects: (i) a
compromised interaction in the int core-RISC state between helix-7
and g7 which was observed for the mutations p.G201C, p.H203Q,
p.M364T, p.A367P and p.S760R, similar to the p.F181A positive
control (Fig. 4a); and (ii) a loss of anchoring of the 3′-end of the
guide (g21) at the PAZ domain, observed for all patient-derived
mutations apart from the p.C751Y in at least one simulated state
(Fig. 4b). The first effect (on the helix-7-g7 interaction) is somewhat
reminiscent of a previously reported mutation in helix-7, which was
shown to affect rapid target recognition by RISC24. The I365α-g7
distance derived from the 3D structure of this mutant was therefore
included here in Fig. 4a for comparison.
Based on these findings, we next addressed the guide-target
duplex unwinding function of AGO2. First, we performed 360ns-
long 1D metadynamics (MetD) simulations of WT and p.L192P
in the duplex-bound complex, in which we enhanced sampling of
I365 intercalation between g6 and g7 using I365δ-g(6,7) distance
as a collective variable (see Supplementary Fig. 14a for the
definition of collective variables). Here, we used the energy
potentials deposited during the MetD simulations to induce
intercalation-mediated partial duplex unwinding, as we could not
calculate the free energy profiles of intercalation. Therefore, the
MetD here provides only a qualitative picture of the possible
unwinding mechanism, allowing us to speculate which aspects of
this process are altered by the patient-derived mutations. As a
simplified metric of the unwinding progress, we used mean guide-
target duplex width (<C1′-C1′>) (Supplementary Fig. 14b).
During unwinding, helix-7 appears to move towards the MID
domain and ‘squeeze’ the RNA duplex at base pairs g4-g7
(Supplementary Fig. 14a, 14c), thereby pushing the two RNA
strands apart (Supplementary video 1). In WT-AGO2 the highest
duplex width reached is slightly larger than in p.L192P (~13 Å vs.
~11.5 Å, respectively), as helix-7 in WT-AGO2 shifted closer to
the MID domain (Supplementary Figs. 14b and 15). However, the
nature of this analysis allowed only for the qualitative comparison
between WT and p.L192P. The movements of the PAZ domain
and helix- 7 towards the opposing AGO2 lobe (MID and PIWI
domains) are concerted (Fig. 4c, gray histogram in the back-
ground), corroborating previous suggestions22,32.
Population distributions of the non-biased MD trajectories of
variants bound to a mismatched duplex (g2-7 holo-RISC) suggest
that compared to WT-AGO2, helix-7 shifted further away from
the MID domain—an effect that seems to be common among all
AGO2 mutants (Fig. 4c; see also Supplemental Fig. 16).
Furthermore, the helix-7-MID distance appeared larger also for
the p.F181A positive control (~1.6 Å larger than WT), but not for
the common non-synonymous AGO2 variant p.E186K. More-
over, a similar effect is also observed when we manually removed
the guide 3′-end from the PAZ domain of the duplex-bound state
(WTΔ(3′-PAZ) in Fig. 4c). This provides a further link between
loss of anchoring of the guide 3′-end at the PAZ domain,
observed for almost all here identified mutations, and AGO2-
mediated guide-target duplex unwinding33. Taken together, based
on our simulations, we hypothesize that the mutations identified
in patients, apart from p.G733R, lead to reduced target release
due to impaired AGO2 unwinding function. However, one should
keep in mind that our data are mostly qualitative, and further,
more quantitative simulations will be needed to completely
dissect how the mutations in AGO2 affect unwinding.
AGO2 germline mutations lead to aberrant density of dendritic
P-bodies. GFP-tagged WT-AGO2 and a representative set of
WTa b c
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Fig. 4 Molecular dynamic simulation of effects of AGO2 mutations. a Distance between the Cα atom of I365 and the glycosidic N atom of the g7 residue
of the guide (I365α-g7(N)). Populations of all core-RISC trajectories were normalized to the same bin number (60). Black and orange dashed vertical lines
denote the reference X-ray structures of the int and nonint core-RISC states (4OLA and 4W5N, respectively). The red dashed line denotes the X-ray
structure of the helix-7 mutant (5WEA). b Distance between the c.o.m. of the 3′-end of the guide and the c.o.m. of the PAZ domain (g21-PAZ) along the
trajectories of all RNA-bound states. Note that the relatively short length of the individual MD trajectories could affect the results. Color code of the states
in both a and b panels: apo-Ago2— green, int core-RISC—gray, nonint core-RISC—orange, g2-8 holo-RISC—magenta and g2-7 holo-RISC—blue. cd motion
of the helix7 and the PAZ domain along the open-closed mode (left panel, gray scale histogram). The histograms are calculated by concatenating the last
100 ns of non-biased trajectory of each variant with mismatched RNA duplex. Colored circles depict the maximum population density of each trajectory.
Black cross denotes the maximum population density of the WT AGO2 with guide RNA. Right panel: population histograms on α7-MID corresponding to
the maxima on the left panel. Equivalent analysis of the variants in in complex with a fully matched seed duplex is shown on Fig. S16.
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identified mutations were expressed in primary cultured rat
hippocampal neurons. Cells were stained for the dendrite marker
MAP2 (Fig. 5a), synaptic marker Shank3 (Supplementary
Fig. 17), and the P-body marker Dcp1a (Fig. 5b). WT-AGO2
formed multiple clearly isolated punctae in cell bodies and
throughout dendrites, consistent with previous observations34–36.
This pattern was maintained for p.F182del, p.L192P and p.
M364T mutants but not for p.G733R, which appeared entirely
diffuse similar to the GFP-control protein (Fig. 5a). In agreement
with the data from non-neuronal cells (Supplementary Fig. 11),
all GFP-AGO2 puncta were identified as P-bodies by co-staining
for Dcp1a (shown for WT in Fig. 5b). Importantly, we found that
whereas the number of AGO2-containing granules in neuronal
cell bodies was not affected by the mutations (Fig. 5c), the density
of dendritic P-bodies was almost doubled upon expression of
mutants p.F182del, p.L192P and p.M364T (Fig. 5d). We conclude
that the reduced phosphorylation at the C-terminal serine cluster,
and the delayed dissociation from mRNA targets leads to an
increased presence of AGO2 at dendritic P-bodies. This indicates
that mutations in AGO2 lead to impairment of local translation
that may result in altered plasticity in response to synaptic
activity34–36. Morphological analyses showed that neurons
expressing WT, p.F182del, p.L192P and p.M364T exhibited a
reduced number of dendrites compared to GFP-control and p.
G733R (Fig. 5a, e). It has been shown previously that expression
of WT-AGO2 is capable of reducing dendritic complexity37, and
again only the p.G733R failed to do so. The number of Shank3
positive clusters in dendrites was similar for all variants, indi-
cating that synaptogenesis is not affected by over-expression of
WT-AGO2 and the AGO2 mutants (Supplementary Fig. 17).
Global transcriptome alteration in primary fibroblasts of
AGO2 patients. Given the major role of AGO2 in post-
transcriptional regulation of gene expression, we next assessed
global changes in the transcriptome in patient-derived primary
dermal fibroblasts. RNA sequencing was performed of primary
dermal fibroblasts obtained from two patients bearing the p.
L192P (cases 2 and 3) and one patient with the p.A367P mutation
(case 14). We compared the expression patterns of the protein-
coding transcripts to fibroblasts from age-matched individuals,
who were either unaffected or bear a causative mutation unrelated
to AGO2. More than 770 genes were differentially expressed (DE)
in case 2 compared to his three age-matched controls, whereas
more than 1500 genes were differentially expressed in both cases
3 and 14, each of which was compared to a single age-matched
control. 485 DE genes overlapped between cases 2 and 3, who
bear the identical de novo p.L192P mutation (Supplementary
Data 2 and 3). All three AGO2-patients shared 164 commonly DE
genes (Fig. 6a, b, Supplementary Data 4), suggesting common but
also mutation-specific effects. Gene ontology enrichment analysis
of the commonly DE genes revealed enrichment for terms related
to mitosis and cell cycle regulation (Supplementary Data 5),
which is in line with the previously described function of AGO2
in regulating accurate chromosome segregation and cell cycle
progression38,39.
Discussion
In this study, we present clinical and molecular findings in 21
individuals bearing heterozygous AGO2 mutations, accompanied
by in-depth functional characterization of identified missense
mutations. All individuals exhibited intellectual disability and



























































































Fig. 5 AGO2 germline mutations lead to an increased number of dendritic P-bodies. a Primary cultured murine hippocampal neurons were transfected
with GFP control or GFP-AGO2WT and variants and Tomato-red. Staining for the dendritic marker MAP2 is shown in gray; inserts display the GFP signal in
cell bodies. Boxed areas are magnified below for GFP- and MAP2 signals. Arrows indicate dendritic GFP-AGO2 clusters. Similar results were obtained in
three independent biological experiments; results are quantified in (c, d, e). Scale bars: 20 μm in overview pictures; 5 μm in inserts. b Neurons expressing
GFP-AGO2 were co-stained for Dcp1a. Similar costaining results were obtained in two biologically independent experiments for wt and F182del, L192P and
M364T mutants, with 30 cells analyzed per experimental condition Scale bar: 5 μm. c–e Quantification of GFP-AGO2 clusters in cell bodies (c), GFP-AGO2
clusters in dendrites (d), and primary dendrites per cell (e). Data for mutant and control conditions were compared to wt. *, **p < 0.05, 0.01, respectively;
Brown–Forsythe and Welch one-way-ANOVA, followed by Dunnett’s T3 multiple comparisons test; n= 3; mean ± SD). Source data are provided as a
Source Data file.
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developmental delay, including delayed motor development and
impaired speech development. Moreover, more than half of the
patients had neonatal feeding difficulties and hypotonia. The
majority of the patients presented with behavioral abnormalities
including features of autistic spectrum disorder and attention
deficit hyperactivity disorder. Some individuals developed
aggressive behavior upon entering puberty. Seizures were a fur-
ther common finding, observed in almost half of the individuals
described here. Although most displayed some dysmorphic fea-
tures, we did not observe a recognizable facial pattern. An
increased incidence of skeletal and heart anomalies was noted.
Interestingly, five individuals presented with plagiocephaly, a
feature which may be related to hypotonia in four individuals.
Furthermore, some specific clinical signs and symptoms were
observed exclusively in individuals bearing the identical mutation.
These include bilateral clinodactyly of the 5th finger as well as
misaligned or crowded teeth with large incisors in all three
individuals carrying the p.C751Y, and central apnea in the
postnatal period in both individuals bearing the p.L192P. We
additionally observed some unique clinical signs and symptoms.
Individual 3 presented with a differential diagnosis of
Pallister–Killian syndrome, individual 14 had blue sclera, indivi-
dual 15 developed hydronephrosis, and individual 20 presented
with precocious puberty. Future clinical reports beyond the large
number of the affected individuals identified in this study will
both broaden genotype-phenotype correlations and likely identify
further mutation-specific clinical features.
Our functional analyses show a clear reduction of activity of
the here identified AGO2 mutations in an shRNA-based silencing
assay. This corroborated the in silico pathogenic predictions. In
several cases we observed only subtle changes, which is consistent
with the overall extreme intolerance of human AGO2 to muta-
tions. Thus, our data show that even minor deficits in AGO2
function are sufficient to elicit aberrant neurological develop-
ment. Currently, our characterization of selected mutations sup-
ports the view that they lead to a loss-of-function rather than a
dominant-negative effect (see Fig. 2f). This is consistent with the
fact that so far only a single homozygous, non-synonymous
AGO2 variant carrier (bearing the p.G88V) is documented in the
gnomAD dataset.
Notably, one of the mutations identified here, p.G733R, stands
out from the others as it fails in almost every functional assay. We
assume that the substitution of the rather bulky and positively
charged Arg for the small Gly will cause structural perturbations
and local unfolding in the PIWI domain, thus leading to a
complete loss of function. In this respect, we predict it to be
functionally similar to the large chromosomal deletion observed
in patient 21. The deletion encompasses part of the AGO2 gene
and is likely to lead to haploinsufficiency. It does not only lead to
loss of the first 3 AGO2 exons, but also the last 23 exons of PTK2.
To our knowledge, no mutation in PTK2 has so far been con-
nected to any human disorder. Several individuals bearing het-
erozygous loss-of-function mutations in PTK2 have been
documented in the gnomAD dataset. Nonetheless, since no
additional individuals with similar AGO2 loss-of-function
mutations, (either a gross deletion, nonsense or frameshift
mutation), are known currently, we cannot deduce to which
extent the additional PTK2 deletion might be contributory. It is
worth noting that the clinical presentation of this individual
somewhat resembles children bearing a deletion that encom-
passes both AGO1 and AGO314.
Currently, the pathomechanism of the p.G573S mutation
remains somewhat unclear. It is conceivable that the change from
glycine to serine, due to the difference in the physico-chemical
properties of these residues, may cause some local structural
changes and alter the interface between PIWI and MID domains.
Importantly, our analyses add physiological and pathological
significance to recent advancements in structural and mechanistic
understanding of ARGONAUTE proteins. The fact that most of
the pathogenic variants in AGO2 alter residues either in L1 or
helix-7 of L2, corroborate the structural analyses showing that
subtle movements at the interface between these two segments
determine the kinetics of target recognition22,24. Furthermore,










Case2 vs Control3a b
Fig. 6 Global transcriptome alteration in primary fibroblasts of AGO2 patients. a, b Venn diagram of upregulated (a) and downregulated (b) transcripts
in fibroblasts isolated from AGO2 patients (cases 2, 3, and 14) compared to five age-matched controls. The number of the upregulated (a) or
downregulated (b) genes in all three cases are marked red, whereas deregulated genes in both cases bearing the p.L192P mutation are marked yellow.
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recently been shown to coincide with the fast release of targets
from RISC29,30. In the AGO2 mutants, we observe reduced
phosphorylation of this cluster, which together with our MD
simulations indicate that the unwinding of guide-target duplexes
may be slowed down by mutations, due to reduced movement of
helix-7 towards the MID domain of the protein.
The reduced phosphorylation and enhanced binding to target
mRNAs of mutant AGO2 coincide with an enhanced appearance
of AGO2-positive dendritic P-bodies in neurons, as observed here
for p.F182del, p.L192P and p.M364T variants. This may con-
tribute to the neuronal phenotype seen in patients, as dendritic P-
bodies and the activity of AGO proteins in dendrites are believed
to contribute to synaptic activity34–36. In particular, it is con-
ceivable that changes in dendritic P-bodies will alter the com-
plement of dendritic mRNAs which may be locally translated
upon synaptic stimuli. Further work will be needed to determine
how this affects neuronal function and morphology, as well as
synaptic plasticity, learning and memory.
Our observation that patient-derived fibroblast cells exhibit
global alterations of gene expression support the view that the
global transcriptome changes due to altered function of AGO2
protein. Interestingly, we observed enrichment for commonly
differentially expressed genes with broad roles in mitosis and cell
cycle regulation, including cell division, mitotic nuclear division,
sister chromatid cohesion, chromosome segregation, microtubule
binding and regulation of cell cycle, to highlight only a few.
Notably, the causal link of neurodevelopmental disorders and
genes encoding for proteins regulating abovementioned processes
have been previously established40–45. It would be interesting to
delineate which of these biological processes are affected in
patient primary fibroblasts. Moreover, given the different organ-
and tissue-specific expression patterns, a further emerging ques-
tion is whether similar transcriptome changes will be observed in
iPSC-derived neurons from these patients or even in patient-
derived cerebral organoids. In addition, further studies are needed
to delineate changes in global miRNA expression and investigate
if these pathogenic mutations result in different RNA and miRNA
binding sites. These analyses will require extensive further work
and will be the main aim of our future studies.
Taken together, our study demonstrates that mutations
affecting a core component of the RNAi machinery are associated
with altered human neurological development, supporting pre-
vious observations that development and function of the nervous
system is particularly vulnerable to alterations in gene expression
patterns and their regulation7.
Methods
Research subjects. Written informed consent for all subjects was obtained in
accordance with protocols approved by the respective ethics committees of the
institutions involved in this study (approval number by the Ethics Committee of
the Hamburg Chamber of Physicians: PV 3802). The authors affirm that the
research participants and their legal representatives, and in the case of minors the
parents or legal representatives of the human research participants provided
informed consent for publication of the images in Supplementary Fig. 2.
Genetic analyses. Some of the investigators presenting affected individuals in this
study were connected through GeneMatcher, a web-based tool for researchers and
clinicians working on identical genes15. Whole-exome sequencing (WES) or trio
whole-exome sequencing (trio-WES) experiments, data annotation and inter-
pretation were performed in nine different centers with slightly different proce-
dures. Trio-WES in families of cases 4, 6, 7, 8, 12, 13, and 16 was performed at the
Radboud University Medical Center in Nijmegen, the Netherlands46. Exome
capture was performed with the Agilent SureSelect Human All Exon v5 enrichment
kit (Agilent Technologies). Whole-exome sequencing was performed on the Illu-
mina HiSeq platform (BGI, Copenhagen, Denmark) and the Illumina Nova-
Seq6000 (NSW Health Pathology Randwick Genomics, Sydney, Australia). Data
were analysed with BWA (read alignment,) and GATK (variant calling) software
packages. Variants were annotated using an in-house developed pipeline.
Prioritization of variants was done by an in-house designed ‘variant interface’ and
manual curation. Trio WES in families of cases 11, 15, 19, and 20 and quad-WES in
a family of cases 17 and 18 were performed on exon targets isolated by capture
using the SureSelect Human All Exon V4 (50Mb) or the IDT xGen Exome
Research Panel v1.0. Massively parallel (NextGen) sequencing was done on an
Illumina system with 100 bp or greater paired-end reads. Reads were aligned to
human genome build GRCh37/UCSC hg19 (for case 11 to GRCh38/UCSC hg38),
and analyzed for sequence variants using custom-developed analysis tools47. The
general assertion criteria for variant classification are publicly available on the
GeneDx ClinVar submission page (http://www.ncbi.nlm.nih.gov/clinvar/
submitters/26957/). Trio-WES in the family of case 2 was performed using a
SureSelect Human All Exon 50Mb V5 Kit (Agilent, Santa Clara, CA, USA), and
sequencing was performed on a HiSeq2500 system (Illumina, San Diego, CA,
USA). Reads were aligned to the human genome assembly hg19 (UCSC Genome
Browser) with Burrows-Wheeler Aligner (BWA, v.0.5.87.5), and detection of
genetic variation was performed using SAMtools (v0.1.18), PINDEL (v 0.2.4t), and
ExomeDepth (v1.0.0)48. Trio-WES in family of case 14 was performed using
SureSelect Human All Exon 50Mb kit (Agilent Technologies, Santa Clara, CA) on
a HiSeq2500 system (Illumina, San Diego, CA, USA). In-house developed scripts
were applied to detect protein changes, affected splice sites and overlaps to known
variations, with filtering against dbSNP build 138, the 1000 Genomes Project data
build November 2014 and ExAC Browser (status from August 2019)49. DNA of
case 9 and his unaffected father was sequenced SureSelect Clinical Research Exome
V2 (Agilent Technologies, Santa Clara, CA) on a HiSeq2500 system (Illumina, San
Diego, CA, USA). The raw data were analyzed using the Care4Rare analysis
pipeline50. DNA of case 1 and his parents were extracted from peripheral blood
using the Gentra Puregene Blood Kit (Gentra Systems Inc., Minneapolis, USA).
Quality and quantity were checked with NanoDrop Spectrophotometer (Nano-
Drop Technologies, Wilmington, USA). Genomic DNA was fragmented by soni-
cation to generate fragments of 200-500 base pairs. Library preparation was done
using Kapa DNA HTP Library Preparation Kit (KAPA Biosystems, 07138008001).
Hybridization of the adapter-ligated DNA was performed to a biotin-labeled probe
included in the Nimblegen SeqCap EZ Human Exome Kit (Roche, 06465692001).
Libraries were sequenced using the Illumina Hiseq 2500 sequencing system and
paired-end 101 bp reads were generated for analysis. Trio-WES in family of case 3
was performed using the SureSelect Human All Exon V4 (50Mb) kit (Agilent,
Santa Clara, CA, USA), and sequencing was performed on a HiSeq2500 system
(Illumina, San Diego, CA, USA). Variants were identified using haplotype caller
within GATK and Freebayes. The intersection of the two variant callers were
annotated with SnpEff and loaded into a database using the GEMINI framework.
Annotations included predicted functional effect (e.g., splice-site, nonsense, mis-
sense), protein position, known clinical associations (OMIM, CLINVAR), mouse
phenotypes (MGI), conservation score (PhastCons, GERP), and effects protein
function (PolyPhen), CADD scores, and population allele frequencies (Exome
Variant Server and Exome Aggregation Consortium data). Trio-Wes in family of
case 5 was performed on MGISEQ-2000 platform (BGI-Wuhan, Wuhan, China).
DNA extraction as well as quality controls were performed using standard meth-
ods. Half a microgram of genomic DNA was randomly fragmented by Covaris.
Using Agencourt AMPure XP-Medium kit fragments of 150-250 bp were selected.
The fragments were then subjected to end-repair, 3′ adenylation and adaptors
ligation. After PCR amplification and purification, hybridization using BGI
Hybridization and Wash kits were used. After a second PCR and recovering step,
the double stranded PCR products were heat-denatured and circularized by the
splint oligo sequence. The single-strand circle DNA (ssCir DNA) were formatted as
the final library. Library was qualified by Qubit ssDNA kit. The library was
amplified to make DNA nanoball which have more than 300 copies of one
molecular. The DNBs were loaded into the patterned nanoarray and pair-end 100
bases reads were generated in the way of sequenced by combinatorial Probe-
Anchor Synthesis (cPAS). The raw data were then transferred to Limbus (Rostock,
Germany) and bioinformatic secondary and tertiary analyses were performed using
the standard algorithms of GATK. SNVs and CNVs were then presented in a web-
based interface and evaluation was performed by experienced scientists. Identified
candidate genes were then prioritized based on in-house scoring system.
Chromosomal Microarray Analysis in family 21 was performed using a 4×180 K
whole-genome oligonucleotide microarray following the manufacturer’s protocol
(Agilent Technologies, Santa Clara, CA, USA). Results were interpreted with
Cytogenomics software v3.0.1.1 (ADM2 method). A CNV was defined as at least
three contiguous oligonucleotides with an abnormal mean log ratio (>0.25 or <
−0.25). GRCh37/hg19 was used as the reference sequence.
Plasmids. An expression vector for GFP-tagged human AGO2 (in pEGFP-C1) was
obtained from Phil Sharp (MIT) via Addgene (#2198151). The vector for Flag/HA
(F/H) tagged human AGO2 has been described before26. Mutations were intro-
duced by site-directed mutagenesis using the QuikChange II kit (Agilent; CA),
using complementary oligonucleotides. Constructs were verified by Sanger
sequencing. For expression in neurons, the entire cDNA fragments coding for
GFP-AGO2 fusion proteins were subcloned into FUW vector which uses a ubi-
quitin promoter for driving expression. FUW was obtained via Addgene #14882
from D. Baltimore, Caltech.
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Antibodies. The following primary antibodies were used: Chicken anti-MAP2
(antibodies Online; ICC: 1:1000); guinea pig anti-Shank3 (Synaptic Systems # 162
304; ICC: 1:500); rabbit monoclonal anti Dcp1a, Abcam #183709; ICC 1:1000);
rabbit anti-Shank and anti-mRFP antisera have been generated by custom
immunization by Biogenes GmbH, Berlin, Germany. Anti-Dicer antibody (Bethyl,
1:1000), anti-HA antibody (Covance Research Products, clone 16B12, 1:1000); anti-
AGO2 (EMD Millipore; clone 11A9; #MABE253; 1:1000); and anti-TNRC6ABC,
clone 7A9 (Merck Millipore) were used for protein detection in Western Blotting.
Secondary antibodies: Alexa fluor 633 goat anti-rb, Alexa 405 goat anti-chk IgG
(abcam), Abberior star red goat anti guinea pig were used at 1:1000 dilution.
Cell lines and transfections. HEK293T, U2OS and HeLa cells were obtained
from ATCC and cultured in Dulbecco’s modified Eagle medium (DMEM;
ThermoFisher) supplemented with 10% fetal bovine serum (FBS; GE Healthcare)
and penicillin-streptomycin (100 U/mL and 100 mg/mL, respectively;
ThermoFisher) under 5% CO2 and at 37 °C. For deletion of the endogenous AGO2
gene, cells were transfected with a Crispr targeting construct in pLentiCrisprV2
(Genscript), carrying a guide sequence encompassing the AGO2 start codon (seq.:
5′-GCCACCATGTACTCGGGAG-3′). Cells were selected with puromycin (2 µg/
ml) for several days. Absence of AGO2 expression was verified by Western blotting.
For silencing assays, cells were plated on 12 well dishes and transfected 4–6 h later
using Turbofect transfection reagent (3.5 µl/well). Cells were transfected with an
expression vector for a gene of interest (mRFP-Shank3, mRFP-DDX1, or GFP-
tagged δ-catenin) in combination with an shRNA vector targeting the
corresponding mRNA. For this, shRNA constructs were generated in pSuper for
DDX1 and δ-catenin and in pLVTHM for Shank3 using target sequences
AGGAGGAGGACCTGATAAA (rat DDX1; bp 1633–1651 in NM_053414.1),
GCAACTATGTCGACTTCTA (mouse δ-catenin; 4240–4258 in NM_008729.3)
and GGAAGTCACCAGAGGACAAGA (rat Shank3; 3794–3814 in
NM_021676.2). For each well either empty vector or AGO2-expression vectors
were added to the transfection mix (1 µg/well).
Primary human dermal fibroblast cultures were established from skin biopsies
taken from the three patients (cases 2,3 and 13) and four age-matched controls
(controls 1, 2, 3, and 5; aged 2, 2, 2, and 15 years at sampling, respectively). In
addition, control 4 (GM01887 aged 7 years at sampling) was obtained from Coriell
Institute. Primary fibroblasts were cultured in the same manner as the cell lines
mentioned above.
Primary dissociated hippocampal neurons isolated from embryonic (E18) rats
were co-transfected after 7 days in vitro (DIV7) with GFP-AGO2 constructs (in the
FUW vector) and pmRFP-C1 using the calcium phosphate method52. The neurons
were fixed at DIV14 and stained for endogenous Shank3 (postsynaptic marker);
MAP2 (dendritic marker) and DCP1a (P-body marker). RFP fluorescence was used
to verify successful transfection. All animal experiments were approved by, and
conducted in accordance with, the guidelines of the Animal Welfare Committee of
the University Medical Center (Hamburg, Germany) under permission number
Org766.
Microscopy. Confocal images of hippocampal neurons were acquired with a Leica
Sp5 confocal microscope using a ×63 objective. Quantitative analysis for images
was performed using ImageJ. Three independent experiments were performed for
all neuron data. Primary dendrites were counted at a ring within 10 µm distance
from the cell body. 12–15 neurons per each condition were counted. For counting
postsynaptic Shank3 clusters, 12–15 neurons per each condition with a total of 45
branches were evaluated. For counting dendritic AGO2-clusters, these were
counted along entire dendritic branches. Cluster density was obtained by dividing
the number of AGO2 clusters/P-bodies by µm of dendrite length. 12–15 neurons
with a total of 36–45 dendrites per each condition were evaluated.
Immunoprecipitation (IP). For immunoprecipitation of overexpressed FLAG/HA-
tagged AGO2 proteins, anti-FLAG M2 affinity agarose gel (Sigma-Aldrich) was
used and washed twice with cold PBS before incubation with lysate. After incu-
bation of 2.5 h at 4 °C on a rotating wheel, the beads with bound proteins were
centrifuged for 1 min at 1000 × g and the supernatant was removed. For qRT-PCR
analysis, the affinity matrix was washed with NET buffer (50 mM Tris/HCl pH 7.5,
5 mM EDTA, 0.5% NP-40, 10% Glycerol, 1 mM NaF, 0.5 mM DTT, 1 mM AEBSF)
+ 300 mM NaCl twice, once with lysis buffer+ 450 mM NaCl, once with 600 mM
NaCl, once with 450 mM NaCl, followed by washing with PBS once. For Western
Blot, Northern Blot and MS analysis, beads were washed three times with NET-
lysis buffer with 300 mM NaCl and once with PBS. Subsequent mass spectrometric
analysis was performed as described below30.
Targeted quantification of AGO2 phosphorylation by SRM (Selected Reaction
Monitoring). Phosphorylation levels of AGO2 variants were quantified by
obtaining selected AGO2 phosphopeptides as well as their non-phosphorylated
counterparts as stable isotope-labeled and quantified spike-in standards from JPT
(Innovative Peptide solutions, Berlin) f30. The following 13C15N-labeled peptides:
SASFNTDPYVR and SApSFNTDPYVR for detection of phospho-S387;
YHLVDKEHDSAEGSHTSGQSNGR and YHLVDKEHDpSAEGSHTSGQSNGR
for detection of pS824; and YHLVDKEHDpSAEGpSHTpSGQpSNGR for detection
of the pS824/pS828/pS831/pS834 cluster, were used to set up a SRM method on a
hybrid triple quadrupole/linear ion trap instrument (QTRAP4500, SCIEX). A
spectral library built from DDA (data-dependent analysis) runs of the heavy
peptides was built and imported into the open source software Skyline (MacCoss
lab software, Seattle, USA). In Skyline, then a targeted method was built according
to the occurrence of precursor charge states +2, +3, +4 during several DDA runs.
After manual inspection of MS2 spectra at least 3 transitions were selected for each
peptide. The resulting transition list was imported into the instrument software
(Analyst 1.6.1) and the following parameters were set: Q1 and Q3 at unit resolution
(0.7 m/z half-maximum peak width), dwell time 20 ms, cycle time < 3 s. After
annotating peptide retention times from the initial SRM run and setting the
following parameters: cycle time: 2 s, retention time window: 5 min, a scheduled
SRM method was created in Skyline. Sample preparation of overexpressed and
immunoprecipitated Flag/HA-tagged Ago2 variants was performed as follows: after
separation on SDS-PAGE AGO2 bands were excised, washed with 50 mM
NH4HCO3, 50 mM NH4HCO3/acetonitrile (3/1), 50 mM NH4HCO3/acetonitrile
(1/1) and lyophilized. AGO2 variant proteins were then subjected to overnight in
gel tryptic digest at 37 °C with ~2 μg trypsin per 100 μl gel volume (Trypsin Gold,
mass spectrometry grade, Promega). Importantly, 100 fmol of each heavy peptide
were spiked into the digests. After digestion, peptides were extracted twice with
100 mM NH4HCO3, followed by 50 mM NH4HCO3 in 50% acetonitrile. The
combined eluates were lyophilized and reconstituted in 20 μl 1% TFA for LC-MS
analysis. The LC-MS/MS system consisted of an UltiMate 3000 RSLCnano System
(Thermo Scientific, Dreieich) coupled via a NanoSpray II source (SCIEX) to a
QTRAP4500 mass spectrometer. Peptides were separated by reversed-phase
chromatography on an Acclaim Pepmap100 C18 nano column (75 μm i.d. × 150
mm, Thermo Fisher) with a C18 Acclaim Pepmap100 preconcentration column
(100 μm i.d. × 20 mm, Thermo Fisher) in front. At a flow rate of 300 nl/min, a 60
min linear gradient of 4–40% acetonitrile in 0.1% formic acid was used. SRM
measurements resulted in.wiff files which were imported back into Skyline. By
calculating the heavy-to-light ratios of the peak areas of the respective transitions
absolute quantification of endogenous phosphorylated or non-phosphorylated
peptides was facilitated. Relative quantification of phosphorylated AGO2 peptides
was performed in Excel by first calculating the absolute amount of either peptide
species, followed by adding up the amounts of the non-modified peptide species
and the related phosphorylated peptide species. Assuming this sum to represent
100%, it was possible to calculate the percentage of the individual phosphopeptide
species.
Quantitative real-time PCR (qRT-PCR). For qRT-PCR analysis of overexpressed
FLAG/HA-tagged AGO2 proteins, the affinity matrix after immunoprecipitation
was washed with lysis buffer+ 300 mM NaCl in total twice, once with lysis buffer
+ 450 mM NaCl, once with 600 mM NaCl, once with 450 mM NaCl, followed by
washing with PBS once. The RNA of Input and IP samples were isolated using
TRIzol (Thermo Fisher Scientific) and a second step with chloroform. For cDNA
synthesis, 1 µg of the Input and complete RNA yield of the IP samples were first
digested with DNaseI (Thermo Fisher Scientific). After the digest, cDNA was
synthesized using the First-Strand cDNA synthesis kit (Thermo Fisher Scientific),
following the manufacturer’s protocol. qRT-PCR was performed with Sso Fast
Eva Green Mix (Bio-Rad). NFIC, fwd 5′-GACCTGTACCTGGCCTACTTTG, rev
5′-CACACCTGACGTGACAAAGCTC; F8A1, fwd 5′-GTTTGCGTCTGGGGA
GGAAT, rev 5′-TGGTAACGTTCAGCCAACGA; HAND1, fwd 5′-GGAGTCC
GCAGAAGGGTTAAA, rev 5′-CGGGCAAGGCTGAAAATGAG; HOXC8, fwd
5′-CGGAGACGCCTCCAAATTCT, rev 5′-GCCTTGTCCTTCGCTACTGT. qRT-
PCRs were run on a CFX96 cycler (Bio-Rad) and data were analyzed using ΔΔCt
method30.
For family survey of case 20, qRT-PCR analysis of AGO2 and PTK2 mRNA was
performed using the kit LightCycler® 480 SYBR Green I Master following the
manufacturer’s protocol (Roche), with detection on a Roche LightCycler 480 Real-
Time PCR instrument (Roche Diagnostics Corporation, USA). SULF1 was used as
reference gene for normalization. The primer pairs were: AGO2, fwd 5′-GATATG
CCTTCAAGCCTCCA, rev 5´-AACTCTCCTCGGGCACTTCT; PTK2, fwd 5′- TG
GGTGAGCTCATCAACAAG, rev 5′- GCCCAAGCATTTTCAGTCTT; SULF1,
fwd 5′- CCCCCAAGAAATGGTCACTA, rev 5′- CAGGCAAGACTGCCCTA
GAC. Data were analyzed using ΔΔCt method.
In vitro cleavage assay. The cap-32P-labeling of target RNA perfect com-
plementary to the endogenous miR-19b, and the in vitro cleavage assay were
performed according to described protocols53,54. For this, 25% of the total
immunoprecipitate was separated for subsequent analysis by Western Blotting.
Thereafter, translation mix was added to a final concentration of 1 × translation
mix and the reaction was started by addition of cap-labeled target RNA. The
reaction was incubated for 1 h at 30 °C and stopped by addition of TRIzol (Thermo
Fisher Scientific) and chloroform, shaking and centrifuging, followed by pre-
cipitation overnight at −20 °C in ethanol with 20 μg glycogen RNA grade (Thermo
Fisher Scientific). After pelleting, the RNA was resuspended in RNA sample buffer.
RNA sequencing and gene expression analysis of primary fibroblasts. Total
RNA was extracted with the RNAeasy mini kit (Qiagen) from primary fibroblasts
that were in all in the same passage 8. These included primary fibroblasts of three
patients bearing AGO2 mutation (cases 2, 3, and 14), 4 age-matched individuals
affected by NDD not related to AGO2 mutation, and an apparently healthy
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individual control 4 (GM01887 aged 7 years at sampling) obtained from Coriell
Institute. RNA integrity and quality was assessed with Epoch Microplate Spec-
trophotometer (BioTek) and on 1% agarose gels. RNA purity was checked using
the NanoPhotometer® spectrophotometer (IMPLEN, CA, USA). RNA concentra-
tion was measured using Qubit® RNA Assay Kit in Qubit® 2.0 Flurometer (Life
Technologies, CA, USA). RNA integrity was assessed using the RNA Nano 6000
Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). Library
preparation and transcriptome sequencing were performed at Novogene. In brief, a
total amount of 3 μg RNA per sample was used as input material for the RNA
sample preparations. Sequencing libraries were generated using NEBNext® Ultra™
RNA Library Prep Kit for Illumina® (NEB, USA) following the manufacturer’s
recommendations and index codes were added to attribute sequences to each
sample. mRNA was purified from total RNA using poly-T oligo-attached magnetic
beads. Fragmentation was carried out using divalent cations under elevated tem-
perature in NEBNext First-Strand Synthesis Reaction Buffer (5× first-strand cDNA
was synthesized using random hexamer primer and M-MuLV Reverse Tran-
scriptase (RNase H-. Second strand cDNA synthesis was subsequently performed
using DNA Polymerase I and RNase H. Remaining overhangs were converted into
blunt ends via exonuclease/polymerase activities. After adenylation of 3′ ends of
DNA fragments, NEBNext Adaptor with hairpin loop structure was ligated to
prepare for hybridization. In order to select cDNA fragments of preferentially
150~200 bp in length, the library fragments were purified with AMPure XP system
(Beckman Coulter, Beverly, USA). Then 3 μl USER Enzyme (NEB, USA) was used
with size-selected, adaptor-ligated cDNA at 37 °C for 15 min followed by 5 min at
95 °C before PCR. Then PCR was performed with Phusion High-Fidelity DNA
polymerase, Universal PCR primers and Index (X) Primer. At last, PCR products
were purified (AMPure XP system) and library quality was assessed on the Agilent
Bioanalyzer 2100 system. The clustering of the index-coded samples was performed
on a cBot Cluster Generation System using HiSeq PE Cluster Kit cBot-HS (Illu-
mina) according to the manufacturer’s instructions. After cluster generation, the
library preparations were sequenced on an Illumina Hiseq platform and 125 bp/
150 bp paired-end reads were generated. Quality trimming and adapter cutting
were performed using Cutadapt v2.5. Genome mapping in paired-end mode was
done using Bowtie2 v2.3.4.1 to the human genome GRCh38.p12. Read counts were
obtained using bedtools v2.26.0 summarized per protein-coding gene using
annotation version GRCh38.97.
Differential expression (DE) analysis was performed by calculating expression
fold-changes for each gene in patients and compared to the age-matched controls.
To account for high variations among (human) individuals we set a threshold of
twofold difference to extract DE genes. Gene ontology enrichment analysis for
molecular function and biological process were obtained using the DAVID
tool v6.8.
Molecular dynamics simulations. WT-AGO2 and AGO2 variants were simulated
in the apo-AGO2 state and in four AGO2-RNA complexes using classical all-atom
MD (Supplementary Fig. 13). In total, 60 non-biased MD trajectories were
obtained; the minimal trajectory length in this set is 200 ns, with a cumulative
simulation time of ~17 μs. All MD simulations were conducted in NAMD 2.1255
using CHARMM36 force field56 in TIP3P57 water box. Production MD simulations
were performed in NVT ensemble using Langevin thermostat at standard condi-
tions with 2 fs integration step. Principal component analysis of Cartesian coor-
dinates of protein Cα atoms was applied to obtain dominant conformational modes
using ProDy58. To induce helix7-mediated duplex unwinding and to probe helix7
movements upon p.L192P mutation and perturbed guide-PAZ interactions, we
performed metadynamics (MetD) simulations (reviewed in ref. 59). In the case of
non-tempered MetD of WT-AGO2 and p.L192P in the complex with a mis-
matched duplex, we aimed at inducing g6-g7 kink by enhancing sampling of I365
intercalation between g6 and g7. The sampling of the collective variable (I365δ-g
(6,7)) was not restrained, leading to sampling outside the grid for Gaussian
potentials deposition. Thus, the potential of mean force (PMF) from this set of
MetD simulations cannot be used. Trajectories from not fully converged MetD
simulations can be used to obtain mechanistic insights but with some restrictions
as discussed in the original reference60. The setup and performance of all simu-
lations are described in detail in Supplementary Methods. Colvar module of
NAMD was used for enhanced sampling simulations61.
Statistical analyses. Statistical analyses were performed with Prism software
(GraphPad, San Diego, CA).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data were submitted to GEO repository under the accession number
GSE141099. The mass spectroscopy data for quantification of AGO2 phoshorylation
have been submitted to the peptideatlas repository under accession PASS01561. The raw
whole-exome sequencing and microarray-based comparative genomic hybridization data
that support the findings in affected individual cannot be made publicly available for
reasons of patient confidentiality. Qualified researchers may apply for access to these
data, pending institutional review board approval. Cells are available upon signing a
material transfer agreement. The data supporting the findings of this study are available
from the corresponding authors upon reasonable request. Source data are provided with
this paper.
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